At least two phase III studies have now demonstrated the benefit of chemoimmunotherapy as first line therapy. The carboplatin/pemetrexed/pembroluzimab regimen, initially reported and FDA approved on the basis of a randomized phase II study has now been validated in the phase III setting (Keynote 189...

I agree with @Martin J. Edelman's approach and the regimen(s) used. I tend to use pemetrexed and carboplatin as my "go to" regimen for non-squamous histology given its excellent tolerability, and use paclitaxel, carboplatin and bevacizumab generally for those not able to use pemetrexed (renal functi...